Low-dose cyclophosphamide synergizes with dendritic cell-based immunotherapy in antitumor activitys

Journal of Biomedicine and Biotechnology

Volumn 2010, Issue , 2010, Pages

  Veltman, Joris D ^a   Lambers, Margaretha E H ^a   Van Nimwegen, Menno ^a   De Jong, Sanne ^a   Hendriks, Rudi W ^a   Hoogsteden, Henk C ^a   Aerts, Joachim G J V ^a   Hegmans, Joost P J J ^a  

^a ERASMUS MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOPHOSPHAMIDE; TRANSCRIPTION FACTOR FOXP3;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER GROWTH; CANCER IMMUNOTHERAPY; CANCER SURVIVAL; CD25+ T LYMPHOCYTE; CD4+ T LYMPHOCYTE; CONTROLLED STUDY; DENDRITIC CELL; DOSE RESPONSE; DRUG CYTOTOXICITY; DRUG EFFICACY; FEMALE; IMMUNOMODULATION; LOW DRUG DOSE; MALIGNANT MESOTHELIOMA; MOUSE; NONHUMAN; OVERALL SURVIVAL; REGULATORY T LYMPHOCYTE; T CELL DEPLETION; THERAPY EFFECT; TUMOR VOLUME;

MUS;

EID: 77953496545     PISSN: 11107243     EISSN: 11107251     Source Type: Journal    
DOI: 10.1155/2010/798467     Document Type: Article

References (58)

1. Robinson B. W. S., Musk A. W., Lake R. A., Malignant mesothelioma The Lancet 2005 366 9483 397 408
2. Banchereau J., Steinman R. M., Dendritic cells and the control of immunity Nature 1998 392 6673 245 252
3. Banchereau J., Palucka A. K., Dendritic cells as therapeutic vaccines against cancer Nature Reviews Immunology 2005 5 4 296 306
4. Steinman R. M., Dhodapkar M., Active immunization against cancer with dendritic cells: the near future International Journal of Cancer 2001 94 4 459 473
5. Hegmans J. P. J. J., Hemmes A., Aerts J. G., Hoogsteden H. C., Lambrecht B. N., Immunotherapy of murine malignant mesothelioma using tumor lysate-pulsed dendritic cells American Journal of Respiratory and Critical Care Medicine 2005 171 10 1168 1177
6. Figdor C. G., de Vries I. J. M., Lesterhuis W. J., Melief C. J. M., Dendritic cell immunotherapy: mapping the way Nature Medicine 2004 10 5 475 480
7. Sakaguchi S., Sakaguchi N., Shimizu J., Immunologic tolerance maintained by CD25+ CD4+ regulatory T cells: their common role in controlling autoimmunity, tumor immunity, and transplantation tolerance Immunological Reviews 2001 182 18 32
8. Hegmans J. P. J. J., Hemmes A., Hammad H., Boon L., Hoogsteden H. C., Lambrecht B. N., Mesothelioma environment comprises cytokines and T-regulatory cells that suppress immune responses European Respiratory Journal 2006 27 6 1086 1095
9. Meloni F., Morosini M., Solari N., Foxp3 expressing CD4+ CD25+ and CD8+ CD8- T regulatory cells in the peripheral blood of patients with lung cancer and pleural mesothelioma Human Immunology 2006 67 1-2 1 12
10. DeLong P., Carroll R. G., Henry A. C., Regulatory T cells and cytokines in malignant pleural effusions secondary to mesothelioma and carcinoma Cancer Biology and Therapy 2005 4 3 342 346
11. Berd D., Mastrangelo M. J., Active immunotherapy of human melanoma exploiting the immunopotentiating effects of cyclophosphamide Cancer Investigation 1988 6 3 337 349
12. Mescher M. F., Rogers J. D., Immunotherapy of established murine tumors with large multivalent immunogen and cyclophosphamide Journal of Immunotherapy 1996 19 2 102 112
13. Liu J.-Y., Wu Y., Zhang X.-S., Single administration of low dose cyclophosphamide augments the antitumor effect of dendritic cell vaccine Cancer Immunology, Immunotherapy 2007 56 10 1597 1604
14. Taieb J., Chaput N., Schartz N., Chemoimmunotherapy of tumors: cyclophosphamide synergizes with exosome based vaccines Journal of Immunology 2006 176 5 2722 2729
15. Goldfarb R. H., Ohashi M., Brunson K. W., Augmentation of IL-2 activated natural killer cell adoptive immunotherapy with cyclophosphamide Anticancer Research 1998 18 3 1441 1446
16. Proietti E., Greco G., Garrone B., Importance of cyclophosphamide-induced bystander effect on T cells for a successful tumor eradication in response to adoptive immunotherapy in mice Journal of Clinical Investigation 1998 101 2 429 441
17. Mihalyo M. A., Doody A. D. H., McAleer J. P., In vivo cyclophosphamide and IL-2 treatment impedes self-antigen-induced effector CD4 cell tolerization: implications for adoptive immunotherapy Journal of Immunology 2004 172 9 5338 5345
18. Li L., Okino T., Sugie T., Cyclophosphamide given after active specific immunization augments antitumor immunity by modulation of Th1 commitment of CD4+ T cells Journal of Surgical Oncology 1998 67 4 221 227
19. Hermans I. F., Chong T. W., Palmowski M. J., Harris A. L., Cerundolo V., Synergistic effect of metronomic dosing of cyclophosphamide combined with specific antitumor immunotherapy in a murine melanoma model Cancer Research 2003 63 23 8408 8413
20. North R. J., Cyclophosphamide-facilitated adoptive immunotherapy of an established tumor depends on elimination of tumor-induced suppressor T cells Journal of Experimental Medicine 1982 155 4 1063 1074
21. Salem M. L., Kadima A. N., El-Naggar S. A., Defining the ability of cyclophosphamide preconditioning to enhance the antigen-specific CD8+ T-cell response to peptide vaccination: creation of a beneficial host microenvironment involving type I IFNs and myeloid cells Journal of Immunotherapy 2007 30 1 40 53
22. Nowak A. K., Lake R. A., Robinson B. W. S., Combined chemoimmunotherapy of solid tumours: improving vaccines? Advanced Drug Delivery Reviews 2006 58 8 975 990
23. Ghiringhelli F., Menard C., Puig P. E., Metronomic cyclophosphamide regimen selectively depletes CD4+ CD25+ regulatory T cells and restores T and NK effector functions in end stage cancer patients Cancer Immunology, Immunotherapy 2007 56 5 641 648
24. Motoyoshi Y., Kaminoda K., Saitoh O., Different mechanisms for anti-tumor effects of low- and high-dose cyclophosphamide Oncology Reports 2006 16 1 141 146
25. Ikezawa Y., Nakazawa M., Tamura C., Takahashi K., Minami M., Ikezawa Z., Cyclophosphamide decreases the number, percentage and the function of CD25+ CD4+ regulatory T cells, which suppress induction of contact hypersensitivity Journal of Dermatological Science 2005 39 2 105 112
26. Lutsiak M. E. C., Semnani R. T., De Pascalis R., Kashmiri S. V. S., Schlom J., Sabzevari H., Inhibition of CD4+25+ T regulatory cell function implicated in enhanced immune response by low-dose cyclophosphamide Blood 2005 105 7 2862 2868
27. Ghiringhelli F., Larmonier N., Schmitt E., CD 4 + CD 25 + regulatory T cells suppress tumor immunity but are sensitive to cyclophosphamide which allows immunotherapy of established tumors to be curative European Journal of Immunology 2004 34 2 336 344
28. van der Most R. G., Currie A. J., Mahendran S., Tumor eradication after cyclophosphamide depends on concurrent depletion of regulatory T cells: a role for cycling TNFR2-expressing effector-suppressor T cells in limiting effective chemotherapy Cancer Immunology, Immunotherapy 2009 58 8 1219 1228
29. van der Most R. G., Currie A. J., Mahendran S., Tumor eradication after cyclophosphamide depends on concurrent depletion of regulatory T cells: a role for cycling TNFR2-expressing effector-suppressor T cells in limiting effective chemotherapy Cancer Immunology, Immunotherapy 2009 58 8 1219 1228
30. Jackaman C., Cornwall S., Lew A. M., Zhan Y., Robinson B. W. S., Nelson D. J., Local effector failure in mesothelioma is not mediated by CD4+ CD25+ T-regulator cells European Respiratory Journal 2009 34 1 162 175
31. Davis M. R., Manning L. S., Whitaker D., Garlepp M. J., Robinson B. W. S., Establishment of a murine model of malignant mesothelioma International Journal of Cancer 1992 52 6 881 886
32. Lutz M. B., Kukutsch N., Ogilvie A. L. J., An advanced culture method for generating large quantities of highly pure dendritic cells from mouse bone marrow Journal of Immunological Methods 1999 223 1 77 92
33. Miyara M., Sakaguchi S., Natural regulatory T cells: mechanisms of suppression Trends in Molecular Medicine 2007 13 3 108 116
34. Sakaguchi S., Regulatory T cells Springer Seminars in Immunopathology 2006 28 1 1 2
35. Yamaguchi T., Sakaguchi S., Regulatory T cells in immune surveillance and treatment of cancer Seminars in Cancer Biology 2006 16 2 115 123
36. Nishikawa H., Kato T., Tawara I., Definition of target antigens for naturally occurring CD4+ CD25+ regulatory T cells Journal of Experimental Medicine 2005 201 5 681 686
37. Sakaguchi S., Immunologic tolerance maintained by regulatory T cells: implications for autoimmunity, tumor immunity and transplantation tolerance Vox Sanguinis 2002 83 supplement 1 151 153
38. Machiels J.-P. H., Reilly R. T., Emens L. A., Cyclophosphamide, doxorubicin, and paclitaxel enhance the antitumor immune response of granulocyte/macrophage-colony stimulating factor-secreting whole-cell vaccines in HER-2/neu tolerized mice Cancer Research 2001 61 9 3689 3697
39. Wada S., Yoshimura K., Hipkiss E. L., Cyclophosphamide augments antitumor immunity: studies in an autochthonous prostate cancer model Cancer Research 2009 69 10 4309 4318
40. Maesen F., Willighagen R., Regression of a malignant tumour of the pleura European Journal of Respiratory Diseases 1987 71 2 135 138
41. Robinson B. W. S., Robinson C., Lake R. A., Localised spontaneous regression in mesotheliomapossible immunological mechanism Lung Cancer 2001 32 2 197 201
42. Schwartz E., Maayan C., Mouallem M., Engelberg S., Friedman E., Malignant peritoneal mesothelioma: long-term spontaneous clinical remission Medical and Pediatric Oncology 1991 19 4 325 328
43. Pilling J. E., Nicholson A. G., Harmer C., Goldstraw P., Prolonged survival due to spontaneous regression and surgical excision of malignant mesothelioma Annals of Thoracic Surgery 2007 83 1 314 315
44. Yanagawa H., Sone S., Fukuta K., Nishioka Y., Ogura T., Local adoptive immunotherapy using lymphokine-activated killer cells and interleukin-2 against malignant pleural mesothelioma: report of two cases Japanese Journal of Clinical Oncology 1991 21 5 377 383
45. Bielefeldt-Ohmann H., Marzo A. L., Himbeck R. P., Jarnicki A. G., Robinson B. W. S., Fitzpatrick D. R., Interleukin-6 involvement in mesothelioma pathobiology: inhibition by interferon immunotherapy Cancer Immunology Immunotherapy 1995 40 4 241 250
46. Astoul P., Picat-Joossen D., Viallat J.-R., Boutin C., Intrapleural administration of interleukin-2 for the treatment of patients with malignant pleural mesothelioma: a phase II study Cancer 1998 83 10 2099 2104 (Pubitemid 28525391)
47. Caminschi I., Venetsanakos E., Leong C. C., Garlepp M. J., Robinson B. W. S., Scott B., Cytokine gene therapy of mesothelioma: immune and antitumor effects of transfected interleukin-12 American Journal of Respiratory Cell and Molecular Biology 1999 21 3 347 356
48. Kruklitis R. J., Singhal S., Delong P., Immuno-gene therapy with interferon- before surgical debulking delays recurrence and improves survival in a murine model of malignant mesothelioma Journal of Thoracic and Cardiovascular Surgery 2004 127 1 123 130
49. Robinson C., Callow M., Stevenson S., Scott B., Robinson B. W. S., Lake R. A., Serologic responses in patients with malignant mesothelioma. Evidence for both public and private specificities American Journal of Respiratory Cell and Molecular Biology 2000 22 5 550 556
50. Banchereau J., Briere F., Caux C., Immunobiology of dendritic cells Annual Review of Immunology 2000 18 767 811
51. Nagaraj S., Gabrilovich D. I., Tumor escape mechanism governed by myeloid-derived suppressor cells Cancer Research 2008 68 8 2561 2563
52. Grossman W. J., Verbsky J. W., Barchet W., Colonna M., Atkinson J. P., Ley T. J., Human T regulatory cells can use the perforin pathway to cause autologous target cell death Immunity 2004 21 4 589 601
53. Cao X., Cai S. F., Fehniger T. A., Granzyme B and perforin are important for regulatory T cell-mediated suppression of tumor clearance Immunity 2007 27 4 635 646
54. Darrasse-Jze G., Bergot A.-S., Durgeau A., Tumor emergence is sensed by self-specific CD44hi memory Tregs that create a dominant tolerogenic environment for tumors in mice Journal of Clinical Investigation 2009 119 9 2648 2662
55. Awwad M., North R. J., Cyclophosphamide-induced immunologically mediated regression of a cyclophosphamide-resistant murine tumor: a consequence of eliminating precursor L3T4+ suppressor T-cells Cancer Research 1989 49 7 1649 1654
56. Ercolini A. M., Ladle B. H., Manning E. A., Recruitment of latent pools of high-avidity CD8+ T cells to the antitumor immune response Journal of Experimental Medicine 2005 201 10 1591 1602
57. Xu L., Xu W., Jiang Z., Zhang F., Chu Y., Xiong S., Depletion of CD4+ CD25high regulatory T cells from tumor infiltrating lymphocytes predominantly induces Th1 type immune response in vivo which inhibits tumor growth in adoptive immunotherapy Cancer Biology and Therapy 2009 8 1 66 72
58. Hori S., Sakaguchi S., Foxp3: a critical regulator of the development and function of regulatory T cells Microbes and Infection 2004 6 8 745 751 (Pubitemid 38781186)